iDerma - Company finances
|
EUR
|
2021
From: 2021-04-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | 3,593 | 46,370 | 120,701 | 206,347 | 248,631 |
| Profit before tax | 2,646 | 1,031 | 13,775 | 11,119 | 12,611 |
| Net profit | 2,646 | 974 | 13,083 | 10,556 | 11,169 |
| Equity | 2,646 | 3,619 | 16,702 | 27,259 | 38,428 |
| Liabilities | 404 | 3,398 | 7,620 | 10,431 | 900 |
| Non-current assets | 0 | 3,668 | 12,822 | 19,956 | 25,924 |
| Current assets | 3,050 | 3,349 | 11,500 | 17,734 | 13,404 |
| Total assets | 3,050 | 7,017 | 24,322 | 37,690 | 39,328 |
|
Taxes paid
|
|||||
| STI taxes | - | - | 10,287 | 19,751 | 22,928 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | +1190.6% | +160.3% | +71.0% | +20.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 86.8% | 13.9% | 53.8% | 28.0% | 28.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 100.0% | 26.9% | 78.3% | 38.7% | 29.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 73.6% | 2.1% | 10.8% | 5.1% | 4.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 73.6% | 2.2% | 11.4% | 5.4% | 5.1% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.2 | 0.9 | 0.5 | 0.4 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 1,797 | 39,745 | 96,561 | 145,653 | 142,075 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
iDerma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-06-06 | 2024-06-09 | 268.98 |
| 2024-06-04 | 2024-06-04 | 266.55 |
| 2023-09-04 | 2023-09-04 | 235.25 |
| 2023-07-19 | 2023-07-20 | 2113.53 |
| 2023-07-11 | 2023-07-11 | 110.45 |
| 2022-08-23 | 2022-09-13 | 74.61 |
| 2022-08-10 | 2022-08-22 | 66.35 |
| 2022-08-09 | 2022-08-09 | 74.97 |
iDerma - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company iDerma is: 0 €
| From | To | Overdue, € |
|---|---|---|
| 2026-09-01 | 2026-09-02 | 0.16 |
| 2026-08-31 | 2026-08-31 | 0.11 |
| 2026-06-23 | 2026-07-07 | 0.73 |
| 2026-06-05 | 2026-06-22 | 48.6 |
| 2026-06-01 | 2026-06-04 | 0.2 |
| 2026-05-31 | 2026-05-31 | 0.15 |
| 2026-05-07 | 2026-05-08 | 1519.31 |
| 2026-05-01 | 2026-05-03 | 0.23 |
| 2026-04-30 | 2026-04-30 | 0.15 |
| 2026-03-27 | 2026-04-08 | 0.4 |
| 2026-03-20 | 2026-03-26 | 0.8 |
| 2026-03-17 | 2026-03-19 | 0.4 |
| 2026-02-18 | 2026-02-18 | 289.68 |
| 2026-02-03 | 2026-02-17 | 0.88 |
| 2026-01-31 | 2026-02-02 | 0.74 |
| 2025-12-17 | 2026-01-30 | 0.42 |
| 2025-12-09 | 2025-12-09 | 1415.79 |
| 2025-12-01 | 2025-12-08 | 0.21 |
| 2025-11-02 | 2025-11-02 | 0.18 |
| 2025-10-05 | 2025-11-01 | 0.15 |
| 2025-10-03 | 2025-10-04 | 1839.11 |
| 2025-10-02 | 2025-10-02 | 33.23 |
| 2025-09-25 | 2025-10-01 | 0.17 |
| 2025-09-01 | 2025-09-03 | 0.21 |
| 2025-08-31 | 2025-08-31 | 0.16 |
| 2025-08-05 | 2025-08-05 | 2105.06 |
| 2025-07-04 | 2025-07-20 | 1539.52 |
| 2025-06-04 | 2025-06-04 | 26.58 |
| 2025-05-20 | 2025-05-20 | 35.63 |
| 2025-05-12 | 2025-05-19 | 35.58 |
| 2025-05-01 | 2025-05-11 | 35.82 |
| 2025-04-14 | 2025-04-30 | 0.38 |
| 2025-04-12 | 2025-04-13 | 0.35 |
| 2025-04-02 | 2025-04-11 | 0.21 |
| 2025-03-15 | 2025-04-01 | 0.16 |
| 2025-03-05 | 2025-03-05 | 2028.18 |
| 2025-02-04 | 2025-02-04 | 1719.23 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
iDerma, MB (code 305727266) is a small partnership engaged in medical specialists activities. In 2025, the company generated revenue of €248.6K and net profit of €11.2K, corresponding to a 4.5% profit margin. Revenue increased by 20.5% year on year and by 106.0% over two years, showing a clear expansion trend from €120.7K in 2023 to €206.3K in 2024 and €248.6K in 2025. Profitability has remained positive, although the margin narrowed from 10.8% in 2023 to 5.1% in 2024 and 4.5% in 2025 as turnover grew faster than earnings. The balance sheet also strengthened: total assets rose to €39.3K in 2025 from €24.3K in 2023, while equity increased to €38.4K. Liabilities stayed very low at €900 in 2025. Latest ratios indicate a strong capital structure, with ROE at 29.1%, ROA at 28.4%, debt-to-equity at 0.02, equity ratio at 97.7% and asset turnover at 6.32x. Revenue per employee was €248.6K, indicating strong productivity.